Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer

2019340 citationsReviewbronze Open Access

Authors

Jianchun Duan · Chinese Academy of Medical Sciences & Peking Union Medical College

Longgang Cui

Xiaochen Zhao

Hua Bai · Chinese Academy of Medical Sciences & Peking Union Medical College

Abstract

Comprehensive analysis suggests that anti-PD-1 exhibited favorable survival outcomes and a safety profile comparable to that of anti-PD-L1, which may provide a useful guide for clinicians.

Topics & Keywords

Cancer Immunotherapy and Biomarkers Pancreatic and Hepatic Oncology Research Lung Cancer Treatments and Mutations

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: JAMA Oncology

Volume 6, Issue 3, pp. 375-375

DOI: 10.1001/jamaoncol.2019.5367

Field-Weighted Citation Impact: 16.67